ArticleApplied microbiology and biotechnology2026
Streamlined cell-free protein synthesis using wheat germ extract.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Wheat germ extract (WGE)-based cell‑free translation is a robust and versatile platform for small‑scale, high‑throughput production of diverse eukaryotic proteins. Although the system has been optimised for efficient protein synthesis using cap‑independent translation‑compatible vectors and bilayer in vitro translation formats, it has traditionally relied on separate transcription and translation steps. To streamline this workflow, a bilayer, coupled in vitro transcription-translation (cIVTT) protocol was developed in which both processes are integrated into a single reaction. After optimisation of the reaction mixture composition and reaction conditions, protein yields comparable to those obtained with the conventional two‑step bilayer in vitro translation method were achieved. Notably, the cIVTT protocol remained effective at reduced temperatures, thereby supporting the enhanced production of human cardiac muscle Troponin I (cTnI), a protein with demanding folding requirements. This simplified and time‑efficient approach enables microgram‑scale protein production and is well suited for high‑throughput applications. KEY POINTS: • Streamlined WGE cell-free protein synthesis workflow • No plasmid linearisation needed before coupled in vitro transcription/translation • Soluble eukaryotic protein yields on par with two‑step bilayer format.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.